PMID- 32719741 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20200928 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 10 DP - 2020 TI - Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer. PG - 954 LID - 10.3389/fonc.2020.00954 [doi] LID - 954 AB - Purpose: PARP inhibitors are a novel targeted anti-cancer drug and a large number of clinical studies on PARP inhibitors have been accomplished. This updated meta-analysis was conducted to evaluate the efficacy and safety of PARP inhibitors in advanced-stage epithelial ovarian cancer. Methods: Medline (PubMed), Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus were searched to identify the eligible trials up to April 2020. ClinicalTrials.gov was also screened for additional unpublished trials. Data extraction and risk of bias assessment were performed by two independent investigators, respectively. The hazard ratios (HRs) and its 95% confidence intervals (CI) for time-to-event data of progression-free survival (PFS) and overall survival (OS), and the risk ratios (RRs) with 95% CI for dichotomous data of overall response rate (ORR) and occurrence of adverse events (AEs) were calculated by Review Manager 5.3 and Stata 12.0 software. Results: A total of 12 trials with 5,347 patients were included in this meta-analysis. Compared with the control group, PARP inhibitors significantly improved PFS (HR, 0.51; 95% CI, 0.40-0.65; P < 0.00001) and ORR (RR, 1.26; 95% CI, 1.11-1.43; P = 0.0003). Specifically, PFS was improved regardless of BRCA genes mutations and homologous-recombination status. However, no difference was observed in OS between the PARP inhibitors group and the control group (95% CI, 0.73-1.01; P = 0.06). PARP inhibitors were associated with a statistically significant higher risk of hematologic events and different PARP inhibitors had different toxicities profiles. Conclusion: PARP inhibitors are an effective and well-tolerated treatment for patients with advanced-stage epithelial ovarian cancer. CI - Copyright (c) 2020 Jiang, Zhao, Zhang, Tian, Yang, Wang, Zhao, Yang, Wang and Yang. FAU - Jiang, Yifan AU - Jiang Y AD - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Zhao, Juan AU - Zhao J AD - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Zhang, Li AU - Zhang L AD - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Tian, Sijuan AU - Tian S AD - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Yang, Ting AU - Yang T AD - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Wang, Li AU - Wang L AD - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Zhao, Minyi AU - Zhao M AD - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Yang, Qing AU - Yang Q AD - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Wang, Yaohui AU - Wang Y AD - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Yang, Xiaofeng AU - Yang X AD - Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. LA - eng PT - Systematic Review DEP - 20200703 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC7350528 OTO - NOTNLM OT - PARP inhibitors OT - epithelial ovarian cancer OT - maintenance treatment OT - meta-analysis OT - niraparib OT - olaparib OT - rucaparib OT - veliparib EDAT- 2020/07/29 06:00 MHDA- 2020/07/29 06:01 PMCR- 2020/01/01 CRDT- 2020/07/29 06:00 PHST- 2020/04/02 00:00 [received] PHST- 2020/05/15 00:00 [accepted] PHST- 2020/07/29 06:00 [entrez] PHST- 2020/07/29 06:00 [pubmed] PHST- 2020/07/29 06:01 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2020.00954 [doi] PST - epublish SO - Front Oncol. 2020 Jul 3;10:954. doi: 10.3389/fonc.2020.00954. eCollection 2020.